HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SOLV
Solventum Corporation
SOLV's fundamentals are weak and it looks expensive: trading at 99x earnings, about nine times its usual 11x. Its downside scenario is more than ten times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SOLV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
SOLV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SOLV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.1x | $8.21 | -91% |
| Fair | 11x | $10.05 | -89% |
| Forward | 12x | $88.81 | — |
| Expensive | 33x | $29.75 | -67% |
| Current | 99x | $88.81 | — |
Historical ranges are pointers, not guarantees.
SOLV's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SOLV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
SOLV has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SOLV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.42 | +725% |
| Q3 2026 | $0.90 | -90% |
| Q2 2026 | $8.19 | +277% |
| Q1 2026 | $8.17 | +276% |
| Q4 2025 | $8.88 | +222% |
| Q3 2025 | $8.69 | +109% |
| Q2 2025 | $2.17 | -65% |
| Q1 2025 | $2.17 | -71% |
| Q4 2024 | $2.76 | -65% |
SOLV has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SOLV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SOLV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | -7% |
| Q2 2026 | $2.2B | +2.2% |
| Q1 2026 | $2B | -3% |
| Q4 2025 | $2B | -3.7% |
| Q3 2025 | $2.1B | +0.7% |
| Q2 2025 | $2.2B | +3.8% |
| Q1 2025 | $2.1B | +2.7% |
| Q4 2024 | $2.1B | +1.9% |
SOLV's revenue has held roughly level: $1.9B last quarter, down 7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | -77 points |
| Q2 2026 | 8.2% | -1.7 points |
| Q1 2026 | 4% | -3.3 points |
| Q4 2025 | 6.2% | -0.3 points |
| Q3 2025 | 81% | +67 points |
| Q2 2025 | 9.9% | -1.8 points |
| Q1 2025 | 7.3% | -12 points |
| Q4 2024 | 6.5% | -13 points |
SOLV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SOLV on cash flow, with more consistent year-over-year improvement.
SOLV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $97M | +$118M |
| Q2 2026 | $144M | +144% |
| Q1 2026 | -$273M | -$193M |
| Q4 2025 | $32M | -65% |
| Q3 2025 | -$21M | -128% |
| Q2 2025 | $59M | -80% |
| Q1 2025 | -$80M | -124% |
| Q4 2024 | $92M | -80% |
SOLV's free cash flow was $0 over the past year, against $50M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SOLV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SOLV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -2.5M shares |
| 1 year | -2.6% | -4.6M shares |
| 3 years | -1.1% | -1.9M shares |
SOLV has 171M diluted shares, down 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $48M |
| Q2 2026 | $288M |
| Q1 2026 | $67M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SOLV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.7x | High |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 5.6x | High |
| Q1 2025 | 5.5x | High |
| Q4 2024 | 4.6x | High |
SOLV's net debt is about 4.7 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SOLV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 49.5 | Neutral |
SOLV's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SOLV PE vs Healthcare Sector
| Metric | SOLV | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 282% above |
| PE % | 99 | 47 | 52 pts above |
SOLV is trading at 99x earnings, a 282% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
SOLV has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus SOLV above 4 of 4.
SOLV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $87.1 | 2% above |
| 20 week MA | $85.8 | 3.5% above |
| 50 week MA | $79.2 | 12% above |
| 100 week MA | $76.0 | 17% above |
SOLV is in an uptrend: it's above all four of its weekly moving averages, and 17% above its 100-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SOLV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $69.6 | $66.7 | -4% |
| 2025 | $66.7 | $80.5 | +21% |
| 2026 YTD | $80.5 | $88.8 | +10% |
SOLV has the edge over HIMS on returns for 2026, with the stronger performance.